Skip to main content
. 2020 Jun 4;7:218. doi: 10.3389/fmed.2020.00218

Table 1.

Characteristics of the 199 patients included in the study.

TOTAL CR DR LR
(n = 199) (n = 120) (n = 36) (n = 43)
Age, yo ± SD 62.5 ± 10.2 61.3 ± 8.9 64.0 ± 10.2 64.7 ± 12.7
Gender, n (%)
   Male 142(71.4) 85(70.8) 26(72.2) 31(72.1)
   Female 57(28.6) 35(29.2) 10(27.8) 12(27.9)
Tumor location, n (%)
   Rhinopharynx 7(3.5) 5(4.2) 1(2.8)* 1(2.3)*
   Oropharynx 124(62.3) 70(58.3) 26(72.2)* 28(65.1)*
   Hypopharynx 24(12.1) 14(11.7) 5(13.9)* 5(11.6)*
   Larynx 31(15.6) 26(21.7) 3(8.3)* 2(4.7)*
   Oral cavity 13(6.5) 5(4.2) 1(2.8)* 7(16.3)*
AJCC stage, n (%)
   I 5(2.5) 5(4.2) 0* 0*
   II 16(8.0) 14(11.7) 0* 2(4.6)*
   III 40(20.1) 28(23.3) 5(13.9)* 7(16.3)*
   IV 138(69.3) 73(60.8) 31(86.1)* 34(79.1)*
RT Duration, (days ± SD) 54.8 ± 9.1 53.4 ± 9.4 56.7 ± 7.5 57.3 ± 8.5
RT Dose, (Gy ± SD) 70.0 ± 1.1 70.0 ± 0.5 70.3 ± 1.2 69.9 ± 1.8
Treatment, n (%)
   CRT 137(68.9) 85(20.8) 26(72.2) 26 (60.5)
   Single RT 56(28.1) 31(25.8) 8(22.2) 17(39.5)

CR, Complete response; DR, Distant relapse; LR, Local relapse; SD, Standard deviation; CRT, Chemo-radiotherapy;

*

Significantly different fromCR.